Citi Pharma (KAR:CPHL) Research & Development: ₨ Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨75.08
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Research & Development?

Citi Pharma KAR:CPHL +0.37% 15 Research & Development is ₨ Mil as of . 20. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Citi Pharma's Research & Development for the six months ended in . 20 was ₨0.00 Mil. Citi Pharma does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in . 20.

Citi Pharma  (KAR:CPHL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Citi Pharma Research & Development Related Terms

Citi Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Research & Development Chart

Citi Pharma Annual Data
Trend
Research & Development

Citi Pharma Semi-Annual Data
Research & Development
KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₨ Mil mean?
Citi Pharma (KAR:CPHL) has a Research & Development of ₨ Mil as of . 20. Research and development expense is the total cost for research and development activities. View historical data on Citi Pharma and its competitors.
Is Citi Pharma's Research & Development too high?
Citi Pharma's current Research & Development is ₨ Mil. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's Research & Development compare to ZTS and UTHR?
Citi Pharma's Research & Development of ₨ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Citi Pharma and its competitors. Citi Pharma's current Research & Development is ₨ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current Research & Development of ₨ Mil. The current Research & Development is ₨ Mil. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current Research & Development is ₨ Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨75.08
Price